DE69824234T2 - Menschliche"CDR-grafted"-Antikörper gegen Gangliosid GM2 - Google Patents

Menschliche"CDR-grafted"-Antikörper gegen Gangliosid GM2 Download PDF

Info

Publication number
DE69824234T2
DE69824234T2 DE69824234T DE69824234T DE69824234T2 DE 69824234 T2 DE69824234 T2 DE 69824234T2 DE 69824234 T DE69824234 T DE 69824234T DE 69824234 T DE69824234 T DE 69824234T DE 69824234 T2 DE69824234 T2 DE 69824234T2
Authority
DE
Germany
Prior art keywords
antibody
chain
region
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69824234T
Other languages
German (de)
English (en)
Other versions
DE69824234D1 (de
Inventor
Nakamura Machida-shi Kazuyasu
Hanai Sagamihara-shi Nobuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of DE69824234D1 publication Critical patent/DE69824234D1/de
Application granted granted Critical
Publication of DE69824234T2 publication Critical patent/DE69824234T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69824234T 1997-03-19 1998-03-19 Menschliche"CDR-grafted"-Antikörper gegen Gangliosid GM2 Expired - Lifetime DE69824234T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6698197 1997-03-19
JP06698197A JP4550947B2 (ja) 1997-03-19 1997-03-19 ガングリオシドｇｍ２に対するヒト型相補性決定領域（ｃｄｒ）移植抗体

Publications (2)

Publication Number Publication Date
DE69824234D1 DE69824234D1 (de) 2004-07-08
DE69824234T2 true DE69824234T2 (de) 2005-06-23

Family

ID=13331716

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69824234T Expired - Lifetime DE69824234T2 (de) 1997-03-19 1998-03-19 Menschliche"CDR-grafted"-Antikörper gegen Gangliosid GM2

Country Status (7)

Country Link
EP (1) EP0882794B1 (enExample)
JP (1) JP4550947B2 (enExample)
AT (1) ATE268382T1 (enExample)
AU (1) AU751948B2 (enExample)
CA (1) CA2226400C (enExample)
DE (1) DE69824234T2 (enExample)
ES (1) ES2219802T3 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407734B1 (en) 1994-10-31 2002-06-18 Nec-Mitsubishi Electric Visual Systems Corporation Power supply system capable of reducing power consumption during interruption of an external input signal given to an operating circuit
US7241568B2 (en) 1996-04-03 2007-07-10 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
ES2601882T5 (es) * 1999-04-09 2021-06-07 Kyowa Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US6693176B1 (en) 1999-07-23 2004-02-17 University Of Massachusetts Antitumor antibodies, proteins, and uses thereof
AU7449200A (en) * 1999-09-30 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Derivatives of antibody against ganglioside gm2
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
AU2016204535C1 (en) * 2000-04-12 2017-02-23 Laboratoire Français Du Fractionnement Et Des Biotechnologies Anti-D monoclonal antibodies
JP2001299349A (ja) * 2000-04-19 2001-10-30 Suntory Ltd 新規組換え型抗体とそのｃｄｒのアミノ酸配列およびそれをコードする遺伝子
HU231090B1 (hu) * 2000-10-06 2020-07-28 Kyowa Kirin Co., Ltd. Antitest-kompozíciót termelő sejt
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2451854A1 (en) * 2001-06-28 2003-01-09 Kyowa Hakko Kogyo Co., Ltd. Humanized antibody against fibroblast growth factor-8 and antibody fragment thereof
WO2003049704A2 (en) 2001-12-11 2003-06-19 University Of Massachusetts Antibodies to treat cancer
WO2003057251A1 (fr) * 2001-12-28 2003-07-17 Kyowa Hakko Kogyo Co., Ltd. Remedes contre l'arthrite
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
US20040115204A1 (en) 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
AU2004279736A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to ganglioside GM2
US20110236374A1 (en) 2007-01-24 2011-09-29 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
FR2953841B1 (fr) * 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
JP5820800B2 (ja) 2010-03-02 2015-11-24 協和発酵キリン株式会社 改変抗体組成物
JP6310397B2 (ja) * 2012-12-06 2018-04-11 国立大学法人金沢大学 中皮腫の治療方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105618C (en) * 1992-09-07 2009-11-03 Kazuyasu Nakamura Humanized antibodies to ganglioside gm2

Also Published As

Publication number Publication date
DE69824234D1 (de) 2004-07-08
EP0882794A3 (en) 1999-06-16
JP4550947B2 (ja) 2010-09-22
EP0882794A2 (en) 1998-12-09
CA2226400C (en) 2008-12-02
AU5942098A (en) 1998-10-01
EP0882794B1 (en) 2004-06-02
JPH10257893A (ja) 1998-09-29
CA2226400A1 (en) 1998-09-19
AU751948B2 (en) 2002-09-05
ATE268382T1 (de) 2004-06-15
ES2219802T3 (es) 2004-12-01

Similar Documents

Publication Publication Date Title
DE69824234T2 (de) Menschliche"CDR-grafted"-Antikörper gegen Gangliosid GM2
DE69333524T2 (de) Humanisierte Antikörper, die mit dem GM2-Gangliosid reagieren
DE69838454T2 (de) Natürlicher menschlicher antikörper
DE69229278T2 (de) Humanisierter b-b10, ein anti-il-2-rezeptor-antikörper
DE69530975T2 (de) Rekombinante humanisierte antikörper gegen lewis y
DE68929167T2 (de) Genexpressions-Elemente und Herstellung von chimären Maus-Mensch-Antikörpern
DE60038252T2 (de) Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3
DE69331903T2 (de) Veränderte Antikörper, damit zusammenhängende Produkte und Verfahren
DE69429095T2 (de) Humanisierte antikoerper
DE69633973T2 (de) Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
DE69535243T2 (de) Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
DE3888186T2 (de) Modulärer zusammenbau von antikörpergenen, dadurch hergestellte antikörper und deren anwendung.
DE3853515T2 (de) Multifunktionelle proteine mit vorbestimmter zielsetzung.
DE69233027T2 (de) Verfahren zur Herstellung humanisierter chimärer Antikörper: Angewandt auf einen gegen Gangliosid GD3 gerichteten chimären Antikörper
DE69100768T2 (de) CD25-bindende Moleküle.
DE69922261T2 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
DE69530763T2 (de) Antikörper gegen e-selektin
DE3751004T2 (de) Chimärer Antikörper mit Spezifität für menschliches Tumor-Antigen.
DE3586440T2 (de) Zur diagnose von menschlichem magen- oder brustkrebs zu verwendender monoklonaler antikoerper.
DE68913658T3 (de) Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
DE68921364T2 (de) Verfahren zur Herstellung von Proteinen mittels rekombinanter DNA.
DE69735596T3 (de) Humanisiertes immunglobulin gegen den alpha4beta7-integrin
DE69030579T2 (de) Verfahren zur herstellung von fusionsproteinen
DE69133200T2 (de) Spezifisch bindende Agentien
DE3783277T2 (de) Monoklonaler antikoerper gegen humanes lungenkarzinom.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: KYOWA HAKKO KIRIN CO., LTD., TOKYO, JP